• 1
    Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40: 581587.
  • 2
    Singh N, Paterson DL. Mycobacterium tuberculosis infection in solid-organ transplant recipients: Impact and implications for management. Clin Infect Dis 1998; 27: 126677.
  • 3
    Ginsburg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nature Med 2007; 13: 290294.
  • 4
    Dorman SE, Chaisson RE. From magic bullets back to the magic mountain: The rise of extensively drug-resistant tuberculosis. Nature Med 2007; 13: 295298.
  • 5
    Blumberg HM, Burman WJ, Chaisson RE et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003; 167: 603662.
  • 6
    Controlling Tuberculosis in the United States. This Official Joint Statement of the American Thoracic Society, the Centers for Disease Control and Prevention, and the Infectious Diseases Society of America was approved by the ATS Board of Directors, June 2004, the Centers for Disease Control and Prevention, November 2004, and the IDSA Board of Directors, March 2005. Am J Respir Crit Care Med 2005; 172: 11691227.
  • 7
    Mycobacterium tuberculosis, in Guidelines for the Prevetnion and Management of Infectious Complications of Solid Organ Transplantation. Am J Transplant 2004; 4(Suppl 10): 3741.
  • 8
    Weisdorf D. Typical and atypical Mycobacterium infections after hemopoietic stem cell or solid organ transplantation. In: BowdenRA, LjungmanP, PayaCV, eds. Transplant Infections. 2nd Ed. Philadelphia , PA : Lippincott Williams & Wilkins; 2003: 250258.
  • 9
    Aguado JM, Torre-Cisneros J, Fortún J, Benito N, Meije Y, Doblas A, Muñoz P. Tuberculosis in solid-organ transplant recipients: Consensus statement of the group for the study of infection in transplant recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 49: 12761284.
  • 10
    Torre-Cisneros J, Doblas A, Aguado JM et al. Tuberculosis after solid-organ transplant:incidence, risk factors, and clinical characteristics in the RESITRA (Spanish network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48: 16571665.
  • 11
    Vikrant S, Agarwal SK, Gupta S et al. Prospective randomized controlled trial of isoniazid chemoprophylaxis during renal replacement therapy. Transpl Infect Dis 2005; 7: 99108.
  • 12
    Agarwal SK, Gupta S, Dash SC et al. Prospective randomised trial of isoniazid prophylaxis in renal transplant recipients. Int Urol Nephrol 2004; 36: 425431.
  • 13
    John GT, Thomas PP, Thomas M, Jeyaseelan L, Jacob CK, Shastry JC. A double-blind randomized controlled trial of primary isoniazid prophylaxis in dialysis and transplant patients. Transplantation 1994; 57: 16831684.
  • 14
    Aguado JM, Herrero JA, Gavalda J et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63: 12781286.
  • 15
    Benito N, Sued O, Moreno A et al. Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002; 74: 13811386.
  • 16
    EPBG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.7.2. Late infections: Tuberculosis. Nephrol Dial Transplant 2002; 17(Suppl): 3943.
  • 17
    Delaney V, Sumrani N, Hong JH, Sommer B. Mycobacterial infections in renal allograft recipients. Transplant Proc 1993; 25: 22882289.
  • 18
    Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994; 58: 301306.
  • 19
    Higgins RSD, Kusne S, Reyes J et al. Mycobacterium tuberculosis after liver transplantation: Management and guidelines for prevention. Clin Transplant 1992; 6: 8190.
  • 20
    Munoz P, Palomo J, Munoz R, Rodriguez-Creixems M, Pelaez T, Bouza E. Tuberculosis in heart transplant recipients. Clin Infect Dis 1995; 21: 398402.
  • 21
    Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995; 152: 374376.
  • 22
    Korner MM, Hirata N, Tenderich G et al. Tuberculosis in heart transplant recipients. Chest 1997; 111: 365369.
  • 23
    Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996; 61: 211215.
  • 24
    John GT, Vincent L, Jeyaseelan L, Jacob CK, Shastry JC. Cyclosporine immunosuppression and mycobacterial infections. Transplantation 1994; 58: 247249.
  • 25
    Peters TG, Reiter CG, Boswell RL. Transmission of tuberculosis by kidney transplantation. Transplantation 1984; 38: 514516.
  • 26
    Sundberg R, Shapiro R, Darras F et al. A tuberculosis outbreak in a renal transplant program. Transplant Proc 1991; 23: 30913092.
  • 27
    Basiri A, Hosseini-Moghaddam  , Simforoosh N et al. The risk factors and laboratory diagnostics for postrenal transplant tuberculosis: A case-control, country-wide study on definitive cases. Transplant Infect Dis 2008; 10: 231235.
  • 28
    Lattes R, Radisic M, Rial M et al. Tuberculosis in renal transplant recipients. Transpl Infect Dis 1999; 1: 98104.
  • 29
    Mazurek GH, Jereb J, Lobue P et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54: 4955.
  • 30
    Pai M, Zwerling A, Menzies D. Systematic review: T cell based assays for the diagnosis of latent tuberculosis infection: An update. Ann Intern Med 2008; 149: 177184.
  • 31
    Manuel O, Humar A, Preiksaitis J et al. Comparison of quantifereon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant 2007; 7: 2797801.
  • 32
    Rubin RH. Infection in the organ transplant patient. In: RubinRH and YoungLS, eds. Clinical approach to infection in the compromised host. 4th Ed. New York and London : Plenum Press, 2002.
  • 33
    Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000; 161(4 Pt 2): S221247.
  • 34
    Thomas PA, Jr., Mozes MF, Jonasson O. Hepatic dysfunction during isoniazid chemoprophylaxis in renal allograft recipients. Arch Surg 1979; 114: 597599.
  • 35
    Schluger LK, Sheiner PA, Jonas M et al. Isoniazid hepatotoxicity after orthotopic liver transplantation. Mt Sinai J Med 1996; 63: 364369.
  • 36
    Bailey WC, Taylor SL, Dascomb HE, Greenberg HB, Ziskind MM. Disturbed hepatic function during isoniazid chemoprophylaxis. Monitoring the hepatic function of 427 hospital employees receiving isoniazid chemoprophylaxis for tuberculosis. Am Rev Respir Dis 1973; 107: 523529.
  • 37
    Antony SJ, Ynares C, Dummer JS. Isoniazid hepatotoxicity in renal transplant recipients. Clin Transplant 1997; 11: 3437.
  • 38
    Singh N, Wagener MM, Gayowski T. Safety and efficiacy of isoniazid chemoprophylaxis administered during liver transplant candidacy for the prevention of posttransplant tuberculosis. Transplantation 2002; 74: 892895.
  • 39
    Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation 2007; 83: 15571562.
  • 40
    Chang KC, Leung CC, Yew WW et al. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am J Respir Crit Care Med 2006; 174: 11531158.
  • 41
    McGregor MM, Olliaro P, Wolmarans L et al. Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 154: 14621467.